Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

Patient Recruitment & Retention Strategies in the 2024 Clinical Trial Landscape

In the landscape of the clinical trial industry in 2024, persistent challenges persist in the realms of patient recruitment and retention. These hurdles, having endured over several years, continue to...

Innovative Trials

- PMLiVE

Solving your biggest patient recruitment and retention challenges

Clinical trial patient recruitment and retention remains one of the key challenges to successfully bringing a new therapeutic to market. An estimated 85% of clinical trials face delays due to...

Innovative Trials

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

GSK’s Jemperli combination approved by FDA for expanded endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

- PMLiVE

Lancet Commission report identifies two new modifiable dementia risk factors

The new risk factors identified are untreated vision loss and high low-density lipoprotein

- PMLiVE

Sanofi and British Transplant Games collaborate to raise awareness of graft versus host disease

The games will see over 1,000 transplant recipients and donors compete in over 25 sporting events

Equal Voice in Virtual Meetings – Perks of Virtual Medical Education

In virtual meetings, every participant has the chance to be heard. Our new video from the "Perks of Virtual Medical Education" series explores how features like chat and Q&A ensure...

Impetus Digital

- PMLiVE

Otsuka Pharmaceutical to acquire Jnana Therapeutics in deal worth over $1.1bn

The agreement includes a clinical-stage drug for the rare inherited metabolic disorder phenylketonuria

- PMLiVE

BeiGene’s Brukinsa recommended by NICE to treat marginal zone lymphoma

Approximately 2,600 cases of the blood cancer are diagnosed in the UK every year

- PMLiVE

Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

- PMLiVE

GSK’s RSV vaccine Arexvy recommended by CHMP for adults aged 50 to 59 years

The positive opinion comes just over a year after Arexvy was approved for those aged 60 and over

- PMLiVE

BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

Melanoma is currently responsible for around 58,000 deaths globally every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links